Asthma and eczema are chronic conditions that can significantly impact a person’s quality of life. These conditions are caused by inflammation in the airways and skin, respectively. Traditional treatment options for asthma and eczema include corticosteroids and immunomodulators, but these treatments can have significant side effects and may not work for everyone.
Dupixent (dupilumab) is a new treatment option approved by the FDA for treating moderate-to-severe asthma and moderate-to-severe eczema. This medication targets a specific protein called IL-4, which plays a crucial role in the inflammation associated with these conditions.
How Does Dupixent Work?
Dupixent is a monoclonal antibody that targets the protein IL-4, a key player in the inflammation associated with asthma and eczema. By blocking IL-4, Dupixent reduces inflammation in the airways and skin, which can significantly improve symptoms.
It is given as an injection, either under the skin or in a vein, and is typically administered every other week. The injection’s dosage and frequency will depend on the individual and their specific condition.
Dupixent has been shown to provide significant benefits for individuals with moderate-to-severe asthma and eczema. In clinical trials, It was shown to improve lung function and reduce the frequency of asthma exacerbations. It also improved the symptoms and quality of life of eczema patients.
One of the significant benefits is that it has fewer side effects compared to traditional treatments such as corticosteroids. Common side effects include injection site reactions, cold sores, and conjunctivitis.
Another benefit of Dupixent is that it can be used in combination with other asthma and eczema treatments, such as inhaled corticosteroids and immunomodulators.
Who is Dupixent for?
Dupixent is a treatment option for individuals with moderate-to-severe asthma and moderate-to-severe eczema. The medication is not recommended for individuals with mild asthma or eczema.
It is important to note that Dupixent is not a cure for asthma and eczema, and individuals will likely need to continue taking it to maintain symptom control. However, it can significantly improve the quality of life for individuals with these conditions.
Clinical studies have demonstrated the efficacy in treating chronic rhinosinusitis with nasal polyps, eczema, and asthma.
● In a clinical trial for adolescents with moderate to severe eczema, 24% of participants noticed cleaner skin, and 37% reported decreased itching over 16 weeks. Clinical investigations on adults with eczema revealed that over 50% of patients experienced a 75% improvement in their skin. After 16 weeks, 36% to 39% of participants had clear or almost clear skin.
● Clinical trials on asthmatics aged six and older revealed that Dupixent could help prevent severe asthma attacks. People’s breathing improved, reducing the frequency they needed to treat their asthma symptoms with oral corticosteroids. Prednisone is an example of an oral corticosteroid that is taken by mouth to relieve inflammation.
● Nasal polyps with chronic rhinosinusitis: In a 24-week clinical trial, those receiving Dupixent reported reduced nasal congestion by between 51% and 59%. Comparatively, those taking a placebo saw improvements of between 16 and 18 percent (a treatment without an active drug). 52% of individuals also reported improvement in their sense of smell. Nasal polyps frequently cause a decreased sense of smell as a side effect.
How to get Dupixent?
Dupixent, a prescription medication, should only be used only when a healthcare professional will be monitoring it. Individuals with moderate-to-severe asthma or eczema should speak with their doctor to see if this is an appropriate treatment option.
Dupixent is a new treatment option for individuals with moderate-to-severe asthma and eczema. By targeting the protein IL-4, Dupixent reduces inflammation in the airways and skin, which can significantly improve symptoms. It has fewer side effects compared to traditional treatments such as corticosteroids and can be used in combination with other asthma and eczema treatments. Dupixent is not a cure for asthma and eczema, but it can significantly improve the quality of life for individuals with these conditions. If you have moderate-to-severe asthma or eczema, consult with your doctor about whether Dupixent is an appropriate treatment option.
Atopic dermatitis flare-ups, itching, and skin discomfort can all be controlled with DUPIXENT. If you have eczema that is difficult to manage, mainly if it affects numerous body parts or is widespread and linked to asthma and seasonal allergies, Contact Kratz Allergy and Asthma now. You can find out more about this treatment option from our specialized doctors and determine whether it is the best choice for you.